What is it about?
Presatovir treatment in comparison to placebo did not significantly improve change in viral load, symptoms, or lung function in 60 lung transplant patients infected with respiratory syncytial virus .
Featured Image
Why is it important?
Transplant patients infected with respiratory viruses may get severely sick and these infections can lead to long term damage. Anti virus treatments are limited
Perspectives
New antivirals for early treatment should be developed and studied in high risk patient cohorts.
Jens Gottlieb
Medizinische Hochschule Hannover
Read the Original
This page is a summary of: A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant, The Journal of Heart and Lung Transplantation, February 2023, Elsevier,
DOI: 10.1016/j.healun.2023.01.013.
You can read the full text:
Contributors
The following have contributed to this page
